Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109030

Prevention and Reversal of Cholera Enterotoxin Effects in Rabbit Jejunum by Nicotinic Acid

Nabila Turjman, Gerald S. Gotterer, and Thomas R. Hendrix

Department of Physiological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Turjman, N. in: JCI | PubMed | Google Scholar

Department of Physiological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Gotterer, G. in: JCI | PubMed | Google Scholar

Department of Physiological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Find articles by Hendrix, T. in: JCI | PubMed | Google Scholar

Published May 1, 1978 - More info

Published in Volume 61, Issue 5 on May 1, 1978
J Clin Invest. 1978;61(5):1155–1160. https://doi.org/10.1172/JCI109030.
© 1978 The American Society for Clinical Investigation
Published May 1, 1978 - Version history
View PDF
Abstract

The cholera enterotoxin produces intestinal secretion associated with an elevation of tissue levels of cyclic adenosine 3′,5′-monophosphate levels of cyclic adenosine 3′,5′-monosphosphate (cAMP). The objectives of this study were to determine whether intestinal secretion and cAMP elevation induced by cholera toxin could be prevented, or once initiated, reversed by nicotinic acid, an agent known to lower tissue levels of cAMP. In rabbits, four jejunal loops were constructed as alternating control (3-ml isotonic electrolyte solution) and cholera toxin (same solution containing 50 μg purified cholera toxin) loops. Net intestinal secretion was determined by measuring fluid accumulation, after which intestinal biopsies were taken for cAMP assay. The animals were pretreated either subcutaneously with 50 mg/kg nicotinic acid in saline 3 h and 1 h before the introduction of cholera toxin, or intraluminally with 200 mg/kg nicotinic acid in Ringer's lactate solution 15 min before the instillation of cholera toxin. Under these conditions, nicotinic acid blocked the cholera toxin-induced secretion and the rise in cAMP measured 3 h after the loops were exposed to cholera toxin. The effect of the nicotinic acid administered within the lumen on net intestinal secretion was studied. Maximal inhibition of net intestinal secretion was achieved with an intraluminally administered dose of nicotinic acid of 100 mg/kg. This dose was chosen for testing the ability of nicotinic acid to reverse the effects of cholera toxin. When nicotinic acid was instilled into a fifth loop constructed distally to the four experimental loops 3 h after exposure of these loops to cholera toxin, both intestinal secretion and elevation of cAMP were reversed. These results suggest that nicotinic acid can prevent and reverse the secretory effects of cholera toxin and may have a role in the therapy of cholera and other cAMP-associated diarrheal diseases.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1155
page 1155
icon of scanned page 1156
page 1156
icon of scanned page 1157
page 1157
icon of scanned page 1158
page 1158
icon of scanned page 1159
page 1159
icon of scanned page 1160
page 1160
Version history
  • Version 1 (May 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts